Meghal examines why claims-level transparency has become increasingly important as manufacturers navigate the growing complexity of 340B and other drug pricing programs. He argues that greater visibility into pricing, discounts, and utilization can help manufacturers move beyond compliance to improve gross-to-net (GTN) management, revenue forecasting, and strategic decision-making.
To learn more, watch the webinar: From Program Silos to GTN Transparency: A Unified View with Model N + Truzo.